Mitchell Sinkler & Starr PA increased its stake in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report) by 33.3% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 2,170 shares of the exchange traded fund’s stock after purchasing an additional 542 shares during the quarter. Mitchell Sinkler & Starr PA’s holdings in SPDR S&P Biotech ETF were worth $212,000 as of its most recent filing with the SEC.
Other institutional investors have also made changes to their positions in the company. ICA Group Wealth Management LLC acquired a new stake in SPDR S&P Biotech ETF in the fourth quarter valued at approximately $27,000. Scarborough Advisors LLC acquired a new stake in SPDR S&P Biotech ETF in the fourth quarter valued at approximately $32,000. BOCHK Asset Management Ltd acquired a new stake in SPDR S&P Biotech ETF in the fourth quarter valued at approximately $36,000. ORG Partners LLC acquired a new stake in SPDR S&P Biotech ETF in the second quarter valued at approximately $40,000. Finally, Vima LLC acquired a new stake in SPDR S&P Biotech ETF in the fourth quarter valued at approximately $45,000.
SPDR S&P Biotech ETF Stock Up 0.8 %
NYSEARCA XBI opened at $98.90 on Thursday. The stock has a market capitalization of $7.54 billion, a PE ratio of 11.47 and a beta of 1.11. The company has a 50 day moving average price of $98.13 and a two-hundred day moving average price of $93.91. SPDR S&P Biotech ETF has a 12-month low of $63.80 and a 12-month high of $103.52.
SPDR S&P Biotech ETF Profile
SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.
Featured Stories
- Five stocks we like better than SPDR S&P Biotech ETF
- When to Sell a Stock for Profit or Loss
- Goldilocks CPI Report Leads Market to Sell Off, Lower Lows Ahead
- The Significance of Brokerage Rankings in Stock Selection
- GameStop: Earnings Won’t Save It, Dilution Points to Trouble
- What are earnings reports?
- Dividend Aristocrats or Dividend Kings: Which Is Best for You?
Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report).
Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.